All News

ANCA, vasculitis, test

ACR/EULAR 2022 Classification Criteria for Granulomatosis with Polyangiitis

d Jack Cush, MD

The ACR/EULAR 2022 revised classification criteria for granulomatosis with polyangiitis (GPA) have been updated with performance characteristics and are validated for use in clinical research.

Read Article
ANCA, vasculitis, test

ACR/EULAR 2022 Classification Criteria for Microscopic Polyangiitis

d Jack Cush, MD

The 2022 ACR/EULAR  classification criteria for microscopic polyangiitis (MPA) have been developed, validated and are now ready for use in clinical research.

Read Article
gout.podagra_0.jpg

Healthy Diets Prevent Gout in Women

d Jack Cush, MD

A prospective cohort from the Nurses’ Health Study has demonstrated that eating a healthy diet results in a 12% to 32% lower risk of incident gout and an even greater risk reduction (65% to 68%) when combined with normal weight and avoiding diuretics.

Read Article
ACR, guidance, guidelines

ACR Newly Revised COVID-19 Vaccine Clinical Guidance for RMD Patients

d ACR

The ACR has updated its clinical guidance for the use of COVID-19 vaccination in patients with musculoskeletal disorders (MSK). 

Read Article
Interested in our most popular articles? Head over to RheumNow. https://t.co/8JLpph3or8

Links:

Dr. John Cush RheumNow ( View Tweet)

Finnish Parkinson’s disease (FINPARK) cohort (22,189) looked at the assoc w/ #RA. RA pts using only chloroquine/hydroxychloroquine was associated with a lower risk of developing PD (adjusted OR 0.74); not with other DMARDs https://t.co/yZhgVT0xLh

Links:

Dr. John Cush RheumNow ( View Tweet)

Systematic review of GI Safety of IL-17 inhibitors included 106 RCTs and 40,053 patients. Inflammatory bowel disease occurred in 0.4%; Most freq Sxs - diarrhea (2.5%), nausea or vomiting (0.7%), and gastroenteritis (0.2%). https://t.co/tv3QXHU1Hg

Links:

Dr. John Cush RheumNow ( View Tweet)

Top Tweet in January Clinical trials generally fail in Sjögren's syndrome; but now a study shows that a biologic B cell inhibitor, ianalumab, met its primary endpoint with a dose-related decrease in disease activity (measured by ESSDAI) at week 24. https://t.co/j0BRs9snVH https://t.co/4OTmbNJ2GP

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Live: Shorter Lectures, More Discussion - Rheumatologists like us, go to meetings like this; meetings that matter; meetings that change thinking We have a packed agenda with experts from around the world. https://t.co/94QmsCqSdj https://t.co/DIJrI8hwDa

Links:

Dr. John Cush RheumNow ( View Tweet)
Study of Academic Clinicians showed that for every $1 generated though office visits (E&M coding) by 5 practicing academic rheums, $12.14 were generated through downstream revenue (mostly infusions). https://t.co/YQ1RL5JF9u

Links:

Dr. John Cush RheumNow ( View Tweet)

The US FDA has published a 52 page report entitled, "DRUG SAFETY PRIORITIES 2021" covering, REMS, Sentinal program, Drug safety communications (eg, Xeljanz), nitrosamine impurities (NMDA), opioids, COVID drug safety & more...https://t.co/vcMZqkdsz5

Links:

Dr. John Cush RheumNow ( View Tweet)

We are excited to announce that Dr. Ernest Choy will be joining us at RheumNow Live, leading a presentation on Precision Medicine in Rheumatoid Arthritis. Join the discussion on March 19-20. Invigorate, Instigate and Debate Rheumatology at #RNL2022 https://t.co/4uXQfRvRgc https://t.co/7KcPXadGcY

Links:

Dr. John Cush RheumNow ( View Tweet)
Following a mild bout of COVID-19, Dr. Kathryn Dao, shares insights on the best way to handle mild cases whether it is yourself or a friend/family member who has COVID19. https://t.co/mevbQVNjPp ( @KDAO2011) https://t.co/CSzB9ChH3r

Links:

Dr. John Cush RheumNow ( View Tweet)
Article in JAMA estimates that there are 110,000 LESS deaths per year when US adults aged 40-85 years or older had a modest increase in their modest increases in moderate-to-vigorous physical activity intensity per day (ie, 10 minutes per day) https://t.co/n1ictmjnqi

Links:

Dr. John Cush RheumNow ( View Tweet)

2021 approved Efgartigimod (Vyvgart) for myasthenia gravis: (binds neonatal Fc receptor, stops Ig recirculation): pts w/ AChR Abs respond best (68% vs 30%). Common AEs include URI, UTI, HA; other AE: eyelid swelling, rash, and SOB. https://t.co/wQKZuAlXoR

Links:

Dr. John Cush RheumNow ( View Tweet)

ICYMI: MMWR reports >40,000 pregnant women who received COVID-19 vaccination during pregnancy- VAX not associated with preterm birth or small-for-gestational-age at birth overall compared with unvaccinated pregnant women. https://t.co/GtRMsNrFnn

Links:

Dr. John Cush RheumNow ( View Tweet)

ICYMI: How Preventable Is Rheumatoid Arthritis? https://t.co/epc6BvYKzq https://t.co/2hKIuE66zT

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: NEJM clinical case -42 yoM w/ red, painful eyes, facial-nerve palsy OS, a large oral ulcer, and petechiae. +ANCA, +PR3. Skin biopsy revealed leukocytoclastic vasculitis with perivascular eosinophils. Dx eosinophilic granulomatosis with polyangiitis https://t.co/zXTQYfPa1t

Links:

Dr. John Cush RheumNow ( View Tweet)

ICYMI: Physical Therapy is More Cost-Effective than Intraarticular Steroids in Knee OA https://t.co/My5xa8vEaP https://t.co/lGL57nwJiZ

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: FDA Approves Skyrizi for Active Psoriatic Arthritis https://t.co/0HpoZYHK2V https://t.co/pvIC6ECqjF

Links:

Dr. John Cush RheumNow ( View Tweet)
×